文献速递淋巴瘤

来那度胺在滤泡性淋巴瘤患者体内触发T细胞效应功能

Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma.
PubMed 文献 · Blood Adv · 2021-01-01

本研究对GALEN试验中44例初治和27例复发/难治滤泡性淋巴瘤患者进行纵向免疫学研究,采用表型、转录组和功能分析,发现来那度胺快速短暂诱导活化T细胞表型,并触发效应记忆T细胞相关基因特征。治疗前及治疗中高效应T细胞和调节性T细胞百分比与不良临床影响相关。

要点

  • 来那度胺快速短暂上调HLA-DR、Tim-3、CD137和PD-1等活化标志物。
  • 来那度胺富集增殖、抗原受体信号和免疫突触修复等效应记忆T细胞基因特征。
  • 治疗前及治疗中高效应T细胞与调节性T细胞百分比提示不良临床影响。

核心结论

  • 来那度胺在滤泡性淋巴瘤患者体内触发T细胞效应功能,为联合治疗设计提供新依据。

研究设计与样本

  • 对GALEN试验中44例初治和27例复发/难治滤泡性淋巴瘤患者进行纵向免疫学研究,含表型、转录组和功能分析。

主要发现

  • 来那度胺快速短暂诱导活化T细胞表型,包括HLA-DR、Tim-3、CD137和PD-1上调。
  • PD-1+与PD-1- T细胞亚群RNA测序显示效应记忆T细胞相关基因特征富集,包括增殖、抗原受体信号和免疫突触修复,并经表型和体外功能实验验证。
  • 治疗前和治疗中高效应T细胞及调节性T细胞百分比与不良临床影响相关。

临床怎么用

  • 研究提示来那度胺通过激活T细胞效应功能发挥作用,支持其与奥妥珠单抗联合用于滤泡性淋巴瘤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The immunomodulatory drug lenalidomide is used in patients with follicular lymphoma (FL) with the aim of stimulating T-cell antitumor immune response. However, little is known about the effects of lenalidomide on T-cell biology in vivo in patients with FL. We thus undertook an extensive longitudinal immunologic study, including phenotypic, transcriptomic, and functional analyses, on 44 first-line and 27 relapsed/refractory patients enrolled in the GALEN trial (Obinutuzumab Combined With Lenalidomide for Relapsed or Refractory Follicular B-Cell Lymphoma) to test the efficacy of lenalidomide and obinutuzumab combination in patients with FL. Lenalidomide rapidly and transiently induced an activated T-cell phenotype, including HLA-DR, Tim-3, CD137, and programmed cell death protein 1 (PD-1) upregulation. Furthermore, sequential RNA-sequencing of sorted PD-1+ and PD-1- T-cell subsets revealed that lenalidomide triggered a strong enrichment for several gene signatures related to effector memory T-cell features, including proliferation, antigen receptor signaling, and immune synapse restoration; all were validated at the phenotypic level and with ex vivo functional assays. Correlative analyses pinpointed a negative clinical impact of high effector T-cell and regulatory T-cell percentages before and during treatment. Our findings bring new insight in lenalidomide mechanisms of action at work in vivo and will fuel a new rationale for the design of combination therapies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ménard C, Rossille D, Dulong J, et al. Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma. Blood Adv. 2021. PMID: 33877296. doi:10.1182/bloodadvances.2020003774

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。